CTRI/2011/12/002292已完成未知
A randomized, open-label, multiple dose, four-way cross-over pharmacodynamic equivalence study comparing orlistat 60 mg and 120 mg hard gelatin capsules [Orlistat (Laboratorios Liconsa S.A. vs alli® (Glaxo Group Limited) and Xenical® (Roche Registration Limited)] in healthy volunteers
aboratorios Liconsa SA0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Healthy Caucasian subjects, males or females >=18 to <=55 years old on the .
- •day of screening
- •2. If females: subjects who are willing to use tampon during menstruation
- •3. Informed Consent Form signed and dated prior to screening procedures.
- •4. BMI >=25.00 to <=30.00 kg/m2 (the minimum body weight for male subjects must be 70 kg, for female subjects - 60 kg)
- •5. Physical examination without any clinically relevant abnormality
- •6. No clinically relevant abnormal laboratory values (as per Annexure 2)
- •7. Subject who accepts the possible weight loss (approximately 10% change from the baseline)
- •8. Subjects who are willing to fast overnight each day and consume the repetitively provided standard meals during the whole study
- •9. Subject able and willing to understand and follow study related procedures
排除标准
- •1. Known allergy or hypersensitivity to orlistat or its derivatives and/or to any study product excipients
- •2. Any known significant current or past acute or chronic disease or condition of the: circulatory system, respiratory system, hematopoietic system, alimentary tract, urinary tract, endocrine system, nervous system, musculoskeletal system, an allergic disease (excluding allergic rhinitis), genetic disorder or psychiatric disorder that could influence the present general health condition, at the Investigators discretion
- •3. Current disease of the alimentary tract, liver or kidneys that may influence
- •absorption, distribution and/or elimination of the studied drugs, as assessed by the Investigator and documented in the medical history
- •4. Current disease of gall bladder and/or cholelithiasis
- •5. The malabsorption syndrome in medical history
- •6. Pancreatitis and/or nephrolithiasis in medical history
- •7. Constipation and/or diarrhea within 1 week before the screening
- •8. Participation in other clinical trials, where at least one dose of study drug was administered, within 30 days preceding the screening
- •9. Blood loss or donation exceeding 300 mL within 4 weeks preceding the screening
- •10. Bradycardia 50 bpm at screening and on day O
- •11. Tachycardia 100bpm at screening and on day O
- •12. Blood pressure: systolic 140mmHg or 90mmHg, diastolic 60 mmHg or 90 mmHg at screening and on day O.
- •13. Body temperature: 36,0°C or 37,5°C on the day of screening and on Day O
- •14. Abnormal clinical laboratory results assessed by Investigator as clinically relevant (CR)
- •15. Positive results of HbsAg and/or anti-HCV and/or anti-HIV tests
- •16. Positive result of stool culture test against Salmonellal Shigella
- •17. Positive result of the stool ova, cysts & parasites (OCP) test
- •18. Clinically relevant abnormalities in ECG recording on the day of screening
- •19. Clinically relevant abnormalities in abdominal USG at screening
- •20. Current or ex-smoker or tobacco user who has stopped smoking less than six (6) months before screening
- •21. Pregnant, breast-feeding females
- •22. History of drug and/or alcohol dependence
- •23. Subjects who adhere to a special diet (e.g. vegetarian, protein, raw food, etc.) within 30 days preceding day 1 in run out period
- •24. of the Administration of drugs which may have an influence subjects condition or study results within 4 weeks preceding the first study drug administration. Only the drugs in dose assessed by the Investigator as safe and not having an impact on the study results are allowed within this time (e.g. paracetamol,
- •25. Ingestion of laxatives and/or fat-blocking nutritional supplements within 14 days preceding day 1 in run-in period
- •26. Positive drug screen or alcohol breath test on day 0
- •27. Alcohol consumption within 96 hours preceding day 1 in run-in period
- •28. Consumption of beverages containing caffeine or other methylxanthines (tea, coffee, cola, chocolate, cocoa, energy drinks) in excessive amount (Le. more than 1 liter daily)
- •29. Any reason the subject is considered by the investigator to be an unsuitable candidate to participate in the study
研究者
相似试验
Unknown
1 期
Bioequivalence Study of Simvastatin 40 mg Film-coated Tablets in Healthy Thai VolunteersHealthy volunteerSimvastatin, Bioequivalence Study, Healthy Thai VolunteerTCTR20230301002International Bio Service Co., Ltd.44
尚未招募
1 期
A randomized, open-labeled, multiple-dose, two-way crossover design with two-period, two-treatment, two-sequence steady-state bioequivalence study of Venlafaxine Hydrochloride Extended-Release Capsules 150 mg and Efexor XR 150 mg Capsules in healthy, adult, Thai volunteers under fed conditioHealthy subjectsBioequivalence Venlafaxine Hydrochloride Extended-Release Capsules 150 mgTCTR20240706012Bio-innova Co., Ltd.44
已完成
不适用
A Randomized, Open-label, Single-dose, Four-sequence, Four -period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix OcasDiseases of The genitoruinary systemKCT0001363Chonbuk National University Hospital36
已完成
不适用
Bioequivalence study for Rifapentine 150 mg TabletsCTRI/2022/04/042197Cipla Ltd India40
已完成
不适用
An open-label, multiple dose, randomized, two-way crossover study to evaluate the effects of BGG492 on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteersEpilepsieEpilepsiafalling diseaseNL-OMON34415ovartis24